Quest Diagnostics Incorporated (NYSE:DGX) SVP Karthik Kuppusamy Sells 1,775 Shares of Stock

Quest Diagnostics Incorporated (NYSE:DGX) SVP Karthik Kuppusamy sold 1,775 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $156.92, for a total transaction of $278,533.00. Following the transaction, the senior vice president now owns 9,734 shares of the company’s stock, valued at approximately $1,527,459.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Karthik Kuppusamy also recently made the following trade(s):

• On Wednesday, August 28th, Karthik Kuppusamy sold 1,990 shares of Quest Diagnostics stock. The stock was sold at an average price of $153.26, for a total value of $304,987.40.

Quest Diagnostics Stock Down 0.0 %

Shares of Quest Diagnostics stock opened at $155.93 on Thursday. Quest Diagnostics Incorporated has a one year low of $123.04 and a one year high of $160.95. The company has a market cap of $17.32 billion, a P/E ratio of 20.99, a PEG ratio of 2.45 and a beta of 0.89. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.91 and a current ratio of 1.00. The firm has a fifty day moving average of $153.38 and a two-hundred day moving average of $145.37.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.04. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The firm had revenue of $2.49 billion during the quarter, compared to analysts’ expectations of $2.43 billion. During the same period in the prior year, the company posted $2.22 earnings per share. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, analysts forecast that Quest Diagnostics Incorporated will post 8.89 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, October 21st. Investors of record on Friday, October 4th were paid a $0.75 dividend. The ex-dividend date was Friday, October 4th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.92%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 40.38%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Van Lanschot Kempen Investment Management N.V. acquired a new position in shares of Quest Diagnostics during the 2nd quarter worth $48,783,000. M&G Plc acquired a new position in Quest Diagnostics during the first quarter worth about $46,432,000. Vanguard Group Inc. increased its holdings in Quest Diagnostics by 2.5% in the first quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock valued at $1,853,151,000 after buying an additional 345,754 shares in the last quarter. Wedge Capital Management L L P NC lifted its position in shares of Quest Diagnostics by 601.7% during the 2nd quarter. Wedge Capital Management L L P NC now owns 277,561 shares of the medical research company’s stock valued at $37,993,000 after acquiring an additional 238,007 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in Quest Diagnostics by 222.0% in the second quarter. Point72 Asset Management L.P. now owns 299,740 shares of the medical research company’s stock valued at $41,028,000 after purchasing an additional 206,640 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Analyst Ratings Changes

DGX has been the subject of several recent analyst reports. Truist Financial boosted their target price on Quest Diagnostics from $158.00 to $165.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Baird R W upgraded shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 23rd. Citigroup increased their target price on shares of Quest Diagnostics from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Robert W. Baird raised shares of Quest Diagnostics from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $157.00 to $182.00 in a research report on Wednesday, October 23rd. Finally, Evercore ISI initiated coverage on Quest Diagnostics in a report on Wednesday, August 28th. They set an “in-line” rating and a $165.00 price objective on the stock. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $164.58.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.